Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology

“…The authors of the DocOx study indicate that response and toxicity profiles are comparable to other commonly used secondline regimens, but did not directly compare this regimen with others [Ettrich et al 2015]. The AGEO study showed that 40% of patients developed grade III and IV toxicities, which has been the downfall of many combination-chemotherapy regimens for pancreatic cancer [Portal et al 2015].…”

Current management and future directions in metastatic pancreatic adenocarcinoma

“…Notably, the median OS was 18 months from the time of first treatment with FOLFIRINOX. 36 Third, can we identify which patients are more likely to respond to gemcitabine-based or 5-FU-based regimens? Currently, there are no biomarkers with which to determine the likelihood of response.…”

“…Although the OS in patients with this disease is typically measured as <1 year, several retrospective and limited prospective studies cited above have noted an OS of 18 months in patients with good PS in this era of modern cytotoxic combination therapy. 36,[40][41][42] Promising New Targets and Treatment Strategies in Patients With Metastatic PAC Beyond cytotoxics, a major unmet need exists for new therapies. Historically, PAC has been characterized as a poorly immunogenic tumor harboring no clear actionable molecular alterations and hallmarked by a dense and inert stroma.…”

“…In a retrospective study evaluating 57 patients receiving gemcitabine and nab‐paclitaxel after experiencing disease progression while receiving FOLFIRINOX, patients received a median of 4 cycles of gemcitabine and nab‐paclitaxel with a disease control rate of 58%, thereby suggesting that this combination can add significantly after first‐line FOLFIRINOX. Notably, the median OS was 18 months from the time of first treatment with FOLFIRINOX …”

“…Although many questions remain regarding the optimal sequencing of therapies in patients with advanced PAC, the advances in the last 5 years have unequivocally improved outcomes. Although the OS in patients with this disease is typically measured as <1 year, several retrospective and limited prospective studies cited above have noted an OS of ≤18 months in patients with good PS in this era of modern cytotoxic combination therapy …”